SRI International said today that it landed a $150 million contract from the National Institutes of Health‘s National Institute of Allergy and Infectious Diseases and the Division of AIDS to support the development of HIV microbicides and other pre-exposure agents. According to the 7-year deal, the research institute will provide preclinical product development services for non-vaccine HIV-prevention products that result from studies or collaborations with companies and organizations.
SRI Biosciences, a division of SRI International, will manufacture and characterize drug products to support promising microbicide and pre-exposure agents through preclinical studies. It will also give support for the required regulatory activities to move products along into clinical testing.
Get the full story at our sister site, Drug Delivery Business News.
The post SRI wins $150m grant to develop HIV prevention products appeared first on MassDevice.